Regarding the identified term (GDF15 Growth/differentiation factor 15), it functions as both a dual biomarker and a therapeutic target in MASLD, with serum concentrations correlating with the severity of hepatic steatosis and predicting the risk of liver cancer in individuals exhibiting a Fib-4 index greater than 1.3-fold [108,109,110]. This evidence concerns the gene GDF15 and Hepatic steatosis.